Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 4 for:    vitamin b3 | Alzheimer Disease

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04430517
Recruitment Status : Recruiting
First Posted : June 12, 2020
Last Update Posted : April 5, 2021
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Fei Du, Mclean Hospital

Brief Summary:
The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain energy metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment (MCI) and mild Alzheimer's dementia (AD).

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Alzheimer Disease Drug: Nicotinamide riboside Early Phase 1

Detailed Description:
Mitochondrial function is mediated, in part, by nicotinamide adenine dinucleotide (NAD). Unfortunately, decreases in NAD+ levels are associated with normal aging, and also with numerous diseases such as AD. Accumulating evidence suggests that NR can enhance mitochondrial function and help slow or reverse these age-related abnormalities. Numerous preclinical and clinical studies have been performed using NR and related compounds to boost NAD+ level in human subjects with various diseases or animal models. However, no studies to date have investigated in vivo metabolic and bioenergetic changes (target engagement) associated with NR supplementation. In this project, we aim to investigate the neurobiological mechanisms and clinical effects of NR in patients with MCI and mild AD using in vivo novel neuroimaging techniques.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia
Estimated Study Start Date : April 7, 2021
Estimated Primary Completion Date : April 30, 2025
Estimated Study Completion Date : April 30, 2025


Arm Intervention/treatment
Experimental: Mild Cognitive Impairment and Alzheimer's Dementia
Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
Drug: Nicotinamide riboside
Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
Other Name: Chromadex NIAGEN




Primary Outcome Measures :
  1. Changes in brain NAD+ [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in brain NAD+ levels

  2. Changes in brain redox state [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in brain NAD+/NADH ratio


Secondary Outcome Measures :
  1. Changes in mitochondrial function [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in brain CK/ATPase activity

  2. Changes in antioxidant glutathione (GSH) levels [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in brain GSH levels


Other Outcome Measures:
  1. Changes in cognitive status [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores. The RBANS provides a total score from 40-160, with a higher score indicating a better outcome.

  2. Changes in functional status [ Time Frame: Baseline, 6 and 12 weeks, pre- and post- 1000 mg NR daily ]
    Changes in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores. The ADCS-ADL provides a total score from 0-78, with a higher score indicating lower severity and a better outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability of the participant and/or his/her legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.
  • Ability to speak and read fluently in English
  • 55-89 years old (inclusive)
  • Normal or corrected to normal hearing and vision
  • Meet clinical diagnostic criteria for MCI or Mild AD, according to the following criteria:

    1. CDR Global Score of 0.5 (MCI) or 1.0 (mild AD)
    2. MoCA total score of 19-25 (MCI) or 11-21 (mild AD)
    3. 2018 NIA-AA guidelines for MCI/mild AD
  • Study partner available for the duration of trial participation
  • At least one copy of the APOE ε4 allele
  • An aggregate risk score > 4 according to the risk analysis method developed by Sabbagh et al. (2017)
  • For individuals who are taking niacin (or a vitamin supplement with niacin) of >200mg, the completion of a two-week wash-out period

Exclusion Criteria:

  • Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician
  • Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician
  • Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician
  • Diagnosis of a mitochondrial disorder
  • Any MRI safety contraindications
  • History of drug hypersensitivity or intolerance to NR
  • Transient ischemic attack or stroke within 1 year prior to screening
  • History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen
  • History of head injury rated as moderate or worse, per DSM-5 criteria
  • History of seizure within prior 10 years
  • Current use of medication with known adverse effects on cognition (benzodiazepines, barbiturates, opiate analgesics, first generation antipsychotic medication, anticholinergics, sedating antihistamines, tricyclic anti-depressants)
  • Change in dose of any psychiatric medications within 4 weeks of screening visit
  • Prior use of L-DOPA, any anti-Parkinsonian medication, or prior treatment with anti-amyloid immunotherapy
  • Current use of putative mitochondrial enhancers and antioxidants (e.g Vitamin E, carnitine, creatine Co-Q10, pramipexole, N-acetyl cysteine [NAC])
  • Initiation of treatment or change in dosing of acetylcholinesterase inhibitors (AChEIs) and memantine within 4 weeks of screening
  • Prior use of prescription narcotics 4 weeks before screening
  • Female subjects who are pregnant or breastfeeding
  • The use of current use of niacin (or a vitamin supplement with niacin) >200mg within the last two weeks prior to study visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04430517


Contacts
Layout table for location contacts
Contact: Fei Du, PhD 6178552710 fdu@mclean.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
McLean Hospital Recruiting
Belmont, Massachusetts, United States, 02478
Contact: Fei Du, PhD    617-855-2710    fdu@mclean.harvard.edu   
Contact: Brent Forester, MD, MSc    (617) 855-3622    bforester@partners.org   
Principal Investigator: Fei Du, PhD         
Principal Investigator: Brent Forester, MD, MSc         
Sponsors and Collaborators
Mclean Hospital
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Fei Du, PhD Mclean Hospital
Principal Investigator: Brent Forester, MD, MSc Mclean Hospital
Layout table for additonal information
Responsible Party: Fei Du, Director, Laboratory for High-Field Imaging and Translational Neuroscience, Mclean Hospital
ClinicalTrials.gov Identifier: NCT04430517    
Other Study ID Numbers: 2020P001652
1R01AG066670 ( U.S. NIH Grant/Contract )
First Posted: June 12, 2020    Key Record Dates
Last Update Posted: April 5, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The proposed research will include data and biosamples from 50 subjects who will receive open-label treatment with nicotinamide riboside (NR) throughout the duration of the 12-week study. At the time of publication of the primary results or within 9 months of database lock, whichever comes first, we will create deidentified datasets, which could be available for research purposes to qualified individuals within the scientific community.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: At the time of publication of the primary results or within 9 months of database lock, whichever comes first, we will create deidentified datasets, which could be available for research purposes to qualified individuals within the scientific community.
Access Criteria: Data are available to users only under a data-sharing agreement. All users will provide to PIs a proposal of hypotheses, variables needed to test these hypotheses, and plans for dissemination of findings. All users will indicate in a signed document: (1) a commitment to using the data only for research purposes and not to identify any participant, clinician, or plan; (2) a plan for securing the data using appropriate technology/data use protocols; (3) an agreement to either destroy or return the data once analyses are completed or by a specific negotiated date; (4) appropriate IRB approval; (5) a commitment that the information provided to users will not be used for commercial purposes, will not be redistributed to third parties, or shared with any others not on the research team; (6) adequate funding/resources to analyze the data and publish results. All findings generated will be described via peer-reviewed articles in scientific journals made available via PubMed Central.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Fei Du, Mclean Hospital:
Mild Cognitive Impairment
Bioenergetics
Alzheimer's Dementia
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Niacinamide
Niacin
Nicotinic Acids
Vitamin B Complex
Vitamins
Dementia
Cognitive Dysfunction
Tauopathies
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents